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The endothelial glycocalyx is a gel-like layer on the luminal side of blood vessels that
is composed of glycosaminoglycans and the proteins that tether them to the plasma
membrane. Interest in its properties and function has grown, particularly in the last
decade, as its importance to endothelial barrier function has come to light. Endothelial
glycocalyx studies have revealed that many critical illnesses result in its degradation
or removal, contributing to endothelial dysfunction and barrier break-down. Loss of
the endothelial glycocalyx facilitates the direct access of immune cells and deleterious
agents (e.g., proteases and reactive oxygen species) to the endothelium, that can then
further endothelial cell injury and dysfunction leading to complications such as edema,
and thrombosis. Here, we briefly describe the endothelial glycocalyx and the primary
components thought to be directly responsible for its degradation. We review recent
literature relevant to glycocalyx damage in several critical illnesses (sepsis, COVID19, trauma and diabetes) that share inflammation as a common denominator with
actions by several common agents (hyaluronidases, proteases, reactive oxygen species,
etc.). Finally, we briefly cover strategies and therapies that show promise in protecting
or helping to rebuild the endothelial glycocalyx such as steroids, protease inhibitors,
anticoagulants and resuscitation strategies.
Keywords: glycocalyx, inflammation, sepsis, trauma, endothelium

GLYCOCALYX OVERVIEW
The glycocalyx is a complex, negatively charged, gel-like layer on the luminal side of endothelial
cells (ECs), which is composed of glycosaminoglycans (GAGs) that are bound to membranespanning proteins that anchor the structure. It is a dynamic structure, with its various components
consistently shed and replaced; in particular, hyaluronic acid (HA) is turned over rapidly (1).
The structure of the glycocalyx depends on the organ and type of endothelium, for example: the
endothelium can be continuous, fenestrated or sinusoid (2); the thickness of the glycocalyx varies
with blood vessel size, ranging from approximately 0.5 µm thick in capillaries (3) to 2.5 µm in
arteries (4); and the pulmonary endothelial glycocalyx can be more than 2 times thicker than in
muscle (5).
The GAGs that constitute the glycocalyx are primarily heparan sulfate (HS), chondroitin
sulfate (CS) and hyaluronic acid (also called hyaluronan or hyaluron). HS and CS are sulfated,
and covalently bound to trans-membrane syndecans-1,4 or membrane-anchored glypican-1. HA
is not sulfated, and is a much larger polymer than the former two, with a molecular weight
often in the hundreds of kilodaltons to megadalton range. Additionally, hyaluronic acid is
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HA shedding or degradation during inflammation in nonliver blood vessels.
Changes in cell-surface HA during inflammation is not limited
to degradation only. HA can form cable-like structures on
the endothelial surface that serve as an attachment site for
monocytes and platelets regardless of their inflammatory status
(19). In addition to enzymatic cleavage, ROS such as hydroxyl
radicals, hypochlorous acid, and peroxynitrite directly degrade
HA (19, 24).

non-covalently bound to multiple membrane-spanning CD44
molecules that are cell-surface glycoproteins involved in cell–cell
interactions, cell adhesion, and migration (6) (Figure 1).
The glycocalyx has a net negative charge that helps determine
interactions with proteins. In particular, it can adsorb positively
charged regions of some plasma proteins and compliments
endothelial barrier function by acting as the first barrier to plasma
protein (which are mostly negatively charged, e.g., albumin)
leakage into the interstitium. Further, by preventing protein leak
from the vasculature, the glycocalyx helps to maintain osmotic
pressure toward the blood vessel’s lumen, thereby inhibiting
water passage into tissues. Finally, the glycocalyx is antithrombotic/profibrinolytic, as well as anti-neutrophil/leukocyte
attachment. These latter mechanisms are achieved through HS
binding of positively charged regions on antithrombin (7, 8)
and by burying cellular adhesion molecules within the depth of
the intact glycocalyx (9). HS in the glycocalyx not only binds
antithrombin, but also enhances its inhibition of thrombin and
factors IXa, Xa (7) and XIa (10).
Exposure to inflammatory stimuli, including TNF-α (11)
and endotoxin (12), as well as inflammatory states such as
sepsis (13, 14), degrade the glycocalyx by triggering release
or activity of various enzymes and/or reactive oxygen species
(ROS) (Figure 2). Glycocalyx degradation exposes the underlying
cell adhesion molecules, thereby promoting leukocyte (15) and
platelet (16) adhesion and inducing a pro-thrombotic state.
The barrier function of the endothelium is compromised by
glycocalyx degradation, increasing its permeability to fluids and
macromolecules, as well as leukocyte migration. Additionally,
denuding the glycocalyx exacerbates EC exposure to proteases
capable of degrading GAG-anchoring proteins, or cell junctions.
A non-exhaustive list of agents which are thought to degrade
various components of the endothelial glycocalyx in disease is
provided in Table 1.

Heparan Sulfate
Heparanase-1 is expressed in platelets (25) and neutrophils
(26), and it is located extracellularly as well as in lysosomes
(27). It degrades HS at sites of inflammation or injury,
thereby contributing to leukocyte attraction (27). Heparanase1 activity is optimal at the acidic pH of approximately 6.4,
and is somewhat active below pH 6.8 (28), suggesting it has
activity in the relatively low pH environment of inflammation.
Additionally, heparan sulfate is cleaved by connective tissue
activating peptide-III (CTAP-III), an N-truncated version of
CXCL7 with endoglycocidic heparinase activity (29). CTAP-III
is expressed in both platelets and neutrophils at similar levels
to heparanase-1 (27, 29). Despite the optimal pH of 5.8, CTAPIII has significant activity up to approximately pH 7.0 (29)
suggesting it too has activity in inflammatory environments.

Chondroitin Sulfate
There are 3 known human hydrolases capable of degrading
CS outside of lysosomes; SPAM1 (also called PH-20, located
mostly in the sperm acrosome), hyaluronidase-1 (see above)
and hyaluronidase-4 (30). Hyaluronidase-4, (also called CS
hydrolase) has a membrane-bound form present in neutrophils
that preferentially hydrolyze CS over HA (30).

Glycosaminoglycan-Related Effects
Hyaluronic Acid

In addition to the direct mechanical and spatial effects, removing
HA from the endothelial surface has other pro-inflammatory
and pro-thrombotic effects, such as removing proteins bound
or adsorbed to the glycocalyx. HA binds protease inhibitors
such as the inter-alpha-trypsin inhibitors, and tumor necrosis
factor-stimulated gene 6, which reduce neutrophil adhesion,
ROS generation, hyaluronidase activity, complement activation
and contributes to matrix metalloproteinase (MMP) inhibition
(19, 31). Additionally, degraded HA fragments (< 500 kDa)
appear to have pro-inflammatory properties of their own (19).
Tissue factor pathway inhibitor (TFPI) binds heparan sulfate
molecules in the glycocalyx (32), helping it to maintain close
proximity to the endothelium; as HS is removed, the pro and
anti-thrombotic balance tilts toward complement activation and
thrombus formation. Additionally, hyaluronidase treatment of
primary human pulmonary vascular endothelial cells in vitro
results in decreased NO production (33), which is necessary for
platelet adhesion to the endothelial surface.

The inflammatory mechanism(s) and enzyme(s) that are
responsible for HA degradation in the vasculature are somewhat
controversial. Hyaluronidase-1 was characterized from serum
nearly 30 years ago (17), but its pH optimum of approximately
3.5 (17) suggests that it would be primarily active in lysosomes
and would have limited activity in plasma. Indeed, data refutes
hyaluronidase-1 as a sheddase in sepsis (18). Hyaluronidase-2
appears to have a membrane-tethered form (19), but again its
pH optimum suggests limited activity in plasma, though platelet
surface-bound hyaluronidase-2 degrades high molecular weight
HA on the endothelial surface into pro-inflammatory fragments
under neutral pH in vitro (20). Further, when hyaluronidase-2
and CD44 are co-expressed on HEK293 cells they extracellularly
degrade HA with a pH optimum between 6.0 and 7.0 (21). The
relatively low pH of inflamed and/or poorly perfused tissues
could impart significant activity to these enzymes, especially
hyaluronidase-2 since endothelial cells co-express CD44. More
recently the protein transmembrane 2 (TMEM2) was shown to
have significant hyaluronidase activity (22). TMEM2 is highly
expressed in endothelial cells, at least of dermal, lymph or liver
origin (22, 23) and functions to degrade free plasma HA in
the liver (23). At present, it is unclear if TMEM2 instigates
Frontiers in Medicine | www.frontiersin.org

Glycosaminoglycan-Anchoring Proteins
Glycocalyx compromise is not only due to GAG degradation,
but also via cleavage of the proteins that anchor the GAGs to
the endothelial plasma membranes. Pre-treating tissues with the
2
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FIGURE 1 | Glycocalyx Structure. HA, dotted red lines, is bound to CD44 in membranes (red). HS (dotted blue) and CS (dashed purple) are covalently bound to
syndecans (yellow) and glypican-1 (orange). Junctional proteins (blue), cellular adhesion molecules (black) adsorbed plasma proteins (green).

FIGURE 2 | Glycocalyx Degradation. The endothelial glycocalyx is degraded by proteases [which remove core proteins’ ectodomains: syndecans (yellow), glipicans
(orange) and CD44 (red)], GAG-degrading enzymes and ROS, leaving free fragments of HA (red dotted), HS (blue dotted) and CS (purple dashed). This exposes
cellular adhesion molecules (black) on the endothelial surface, allowing easier binding of white blood cells [e.g., neutrophils (PMNs)] and platelets. Neutrophils can
release additional proteases, further damaging core glycocalyx proteins, junctional proteins (blue) and produce additional ROS. With a degraded glycocalyx, blood
flows closer to the endothelial cells and plasma proteins (green), can access the endothelial surface.

broad-spectrum MMP inhibitor doxycycline inhibited glycocalyx
shedding and leukocyte adhesion in a murine inflammation
model (34), demonstrating the crucial role for MMP-induced
glycocalyx breakdown. More specifically, the membrane-bound
MMP14 has been shown to cleave syndecan-1 (35) and CD44
(36). Additionally, syndecan-1 and syndecan-4 are cleaved by
MMPs 2, 3, 7, 9, and 14, (37) as well as ADAM17 (38).

cited herein, with the component studied, biochemical thresholds
and/or statistical value is provided in Table 2.

Sepsis
Sepsis is defined as life-threatening organ dysfunction caused by
a dysregulated host response to infection (39). Degradation of
the glycocalyx encountered during sepsis conforms to the pattern
seen in many severe inflammatory diseases. The systemic proinflammatory stimuli (e.g., cytokines, lipopolysaccharide, ROS)
produced during sepsis are the initiating factors in a feed-forward
cascade of inflammation and glycocalyx degradation (40, 41).
The degraded glycocalyx allows the binding and extravasation
of leukocytes, as well as platelet recruitment (40, 41), thereby
resulting in further inflammation and greater risk of thrombosis.
Further, glycocalyx loss leads to capillary leaking that contributes

DISEASE-SPECIFIC GLYCOCALYX
ALTERATIONS
Several major glycocalyx components have been used as
biomarkers to distinguish sub-populations in critical illness and
injury, as well as to prognosticate outcomes. A list of the literature

Frontiers in Medicine | www.frontiersin.org
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On the day of intensive care unit (ICU) admission,
sepsis patients showed a significantly higher median plasma
concentration of HA and HS compared to controls, with those
who died in the next 90 days displaying a significantly higher
concentration within the sepsis population (43). In the same
study, plasma HA and HS correlated with IL-6, IL-10, and
sequential organ failure assessment (SOFA) score. A later study
confirmed higher concentrations of HA, as well as syndecan-1,
in sepsis patients at multiple time points of illness (44). HA and
syndecan-1 concentrations were also higher for the first five ICU
days in severe sepsis (sepsis with acute organ dysfunction) and
septic shock (sepsis with refractory hypotension despite adequate
fluid loading) patients, when compared to sepsis. Furthermore,
HA and syndecan-1 were elevated for at least the first 3 days
in septic shock vs. severe sepsis patients. More importantly,
in survivors, the HA and syndecan-1 concentrations tended to
decrease over the ICU stay, while they tended to slightly increase
or stay the same in non-survivors. Both glycocalyx components
were correlated with Acute Physiologic Assessment and Chronic
Health Evaluation II (APACHE II) and SOFA scores; cutoff values
of < 441 ng/mL HA on ICU day 7 or < 898 ng/mL syndecan-1 on
ICU day 5 were found to predict 90 and 87% survival, respectively
(44). Another study showed that plasma HA is increased in septic
shock patients compared to healthy controls, but not pancreatitis
patients (18). Interestingly, this same study showed that plasma
hyaluronidase activity was actually lower in septic shock patients,
compared to healthy controls. While plasma hyaluronidase
measurements may prove to be interesting diagnostically or
functionally, it’s not clear if the plasma hyaluronidase (HYAL1),
can act as a HA sheddase in either sepsis or other inflammatory
diseases. HYAL2 is membrane-bound and has a pH optimum
closer to that of inflamed tissues, though its activity would
not be present in plasma tests due to its anchoring in the
plasma membrane.
Patients with non-pulmonary sepsis, on mechanical
ventilation and with an APACHE II ≥ 25, had higher plasma
syndecan-1 concentrations on day 2 of ICU admission with levels
that were significantly correlated with acute respiratory distress
syndrome (ARDS), though this was not true of pulmonary sepsis
patients (pneumonia or aspiration of gastric contents) (14). In
those patients that developed ARDS, syndecan-1 levels were
higher than in those that developed ARDS from non-pulmonary
sepsis. Additionally, syndecan-1 levels were associated with
vasopressor requirements, and circulatory, hepatic, renal,
and coagulation failures (14). Moreover, higher syndecan-1
concentrations were independently predictive of in-hospital
mortality. There was no correlation between syndecan-1 and
plasma myeloperoxidase concentrations, used as a marker of
neutrophil activation (a source of proteases).
While syndecan-1, HA and HS were significantly higher in
septic shock patients compared to sepsis patients, and syndecan1 was good at predicting progression to septic shock (81.8%
sensitivity, 78.3% specificity), interestingly, it was not higher
in non-survivors, vs. survivors (45). In contrast, the authors
did identify significantly increased plasma concentrations of
HS in non-survivors, compared to survivors (204.5 vs. 158.9
ng/mL). All three glycocalyx components measured had a weak

TABLE 1 | Glycocalyx-degrading agents in critical illness.
Component

Degrading agent during
critical illness

References

Hyaluronic acid

HYAL1, HYAL2, TMEM2, ROS

(17, 20–24)

Heparan sulfate

HYAL1, HEPase1, CTAP-III

(25–27, 29)

Chondroitin sulfate

HYAL4

(30)

Syndecan-1

MMP2,3,7,9, and 14, ADAM17

(35, 37, 38)

Syndecan-4

MMP2,3,7,9, and 14, ADAM17

(37, 38)

CD44

ADAM15, MMP14

(36, 126)

ADAM, a disintegrin and metalloproteinase; CTAP-III, connective tissue
activating peptide-III; HEPase1, Heparanase-1; HYAL, hyaluronidase; MMP, matrix
metalloproteinase; TMEM2, transmembrane 2; ROS, reactive oxygen species.

TABLE 2 | Glycocalyx components used as biomarkers.
Component

Threshold/
Value

Population,
measure

PBR

AUC = 0.778

Sepsis, in-hospital mortality

AUC = 0.75

COVID-19, 60-day mortality

(56)

OR = 1.850

Sepsis, in-hospital mortality

(14)

AUC = 0.781

Sepsis, in-hospital mortality

(42)

898 ng/mL,
AUC = 0.801

Sepsis, 90-day mortality

(44)

Syndecan-1

HR = 1.95

Septic shock, 90-day mortality

(46)

COVID-19, in-hospital mortality

(61)

COVID-19, critical vs severe

(63)

OR = 1.01, p = 0.043 Trauma, 30-day mortality

(74)

40 ng/mL,
Trauma, 30-day mortality
AUC = 0.71, OR = 2.23

(76)

p < 0.05
p < 0.0001

Heparan
sulfate

(42)

813.8 ng/mL,
AUC = 0.783
p < 0.0001

Hyaluronic
acid

References

T1D, nephropathy vs not

(95)

T1D, microalbuminuria vs not

(96)

p = 0.006

Sepsis, 90-day mortality

(43)

441 ng/mL, AUC =
0.827

Sepsis, 90-day mortality

(44)

p < 0.001

COVID-19, ICU vs non-ICU

(60)

p < 0.05

Trauma, coagulopathy vs not

(77)

p < 0.05

T1D, microalbuminuria vs not

(90)
(43)

p = 0.02

Sepsis, 90-day mortality

p < 0.05

Sepsis, 28-day mortality

(45)

p < 0.05

COVID-19, ICU vs non-ICU

(60)

p < 0.001

COVID-19, critical vs moderate

(63)

p < 0.05

Trauma, autoheparinization vs
not

(71)

AUC, area under the curve for a receiver-operator characteristic; HR, hazard ratio;
ICU, intensive care unit; OR, odds ratio; PBR, perfused boundary region, a measure
of glycocalyx thickness; T1D, type-1 diabetes.

to systemic edema, hypovolemia, and along with thrombi,
contribute to circulatory dysfunction (41). Ultimately, the above
events result in hypoperfusion of tissues and organ damage that
is a hallmark of sepsis (40, 41).
Measurements of the perfused boundary region in sublingual
micro-vessels (a measurement of glycocalyx thickness), showed
the glycocalyx is thinner in sepsis non-survivors than survivors,
and admission perfused boundary region was associated with
hospital mortality (AUC 0.778) (42).

Frontiers in Medicine | www.frontiersin.org
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death in non-critically ill hospitalized COVID-19 patients (52),
highlighting the importance of thrombosis in COVID-19 disease.
Early in the pandemic, we investigated plasma from
age- and sex-matched subjects, including COVID-19 ICU
patients, non-COVID-19 ICU patients and healthy controls
(33). Compared with healthy control subjects, COVID-19
positive patients had higher plasma von Willebrand factor,
and glycocalyx-degradation products (chondroitin sulfate
and syndecan-1). When compared with COVID-19 negative
sepsis patients, COVID-19 positive patients had persistently
higher soluble P-selectin, hyaluronic acid, and syndecan-1,
particularly on ICU day 3 and thereafter. In fact, syndecan1 continued to increase over the 7 days that COVID-19
patients were tested. Our data suggested that glycocalyx
degradation was greater in COVID-19 patients, as opposed to
age- and sex-matched non-COVID-19 ICU patients, perhaps
explaining the greater risk of thrombosis in COVID-19 (33).
As proof of principle, we removed surface hyaluronic acid
from human pulmonary microvascular endothelial cells with
hyaluronidase treatment resulting in depressed nitric oxide
production, an instigating mechanism for platelet adhesion to
the microvascular endothelium.
Additionally, we published a case report of a 15year old female admitted to hospital with multi-system
inflammatory syndrome associated with COVID-19 (MIS-C),
and demonstrated that plasma HA was increased almost 7fold over age and sex-matched healthy controls (55). Further,
MMP7, which is known to cleave syndecans-1 and 4 (Table 1),
was the most up-regulated analyte tested (over 15-fold) (55).
These latter data were consistent with endothelial glycocalyx
degradation following SARS-CoV-2 infection, albeit with a
MIS-C presentation.
Measuring the perfused boundary region of sub-lingual blood
vessels has become a useful bedside indicator of glycocalyx
damage. Mechanically ventilated COVID-19 patients have been
shown to have a thinner glycocalyx, compared to non-ventilated
COVID-19 patients or healthy controls (56). The same study
showed that plasma concentrations of HA were significantly
higher in both non- and ventilated COVID-19 patients compared
to controls, while syndecan-1 was higher in ventilated COVID
patients compared to both non-ventilated COVID-19 patients
and controls. Additionally syndecan-1 predicted development of
moderate-to-severe ARDS (AUC 0.91), and a thinner glycocalyx
was associated with 60-day mortality (56).
Subsequent studies have reported increased plasma syndecan1 (57, 58) and HA (57, 59) in COVID-19 patients compared
to healthy controls. One study showed plasma HA, HS, and
CS were all increased in COVID-19 patients compared to
healthy controls, but lower or similar to sepsis patients; though
COVID-19 ICU patients had significantly higher concentrations
of HA and HS compared to non-ICU COVID patients (60).
Additionally, plasma hyaluronidase activity was higher in the
ICU COVID-19 patients vs. the non-ICU patients, and plasma
MMP2, MMP9 and cathepsin D activities (enzymes which may
cleave GAG-anchoring proteins) were significantly increased
in COVID-19 patients vs. healthy controls (60). Interestingly,
COVID-19 patient plasma HA was also found to be low

to moderate correlation with disease severity as assessed by
either APACHE II or SOFA scores (r ≤ 0.5) (45). Further,
plasma syndecan-1 and HA concentrations were found to be
significantly higher in a subset of patients with disseminated
intravascular coagulation (DIC), and may be useful predictors of
DIC, underscoring the importance of the anti-fibrinolytic actions
attributed to the glycocalyx.
More recently, syndecan-1 plasma concentrations in septic
shock patients were found to be more than double that of
healthy volunteers on day 1 of ICU admission and were
significantly associated with the general SOFA score and the
coagulation SOFA subscale (46). Syndecan-1 concentrations were
significantly associated with the need for renal replacement
therapy, or slow dialysis provided to hemodynamically unstable
patients, as well as the incidence of coagulation failure and 90day mortality (46). Interestingly, many of these associations were
found oppositely correlated with sphingosine 1-phosphate which
protects syndecan-1 from shedding.
In sepsis cases, the coagulation system can become
pathologically activated, resulting in DIC and thrombosis.
Whole-blood measurements of coagulation in sepsis patients
can reveal a hypo-, normal or hyper-coagulable state (47), while
traditional lab tests may show the plasma is not hypercoagulable
per se (48), leading to the hypothesis that endothelial dysfunction
may be a major contributing factor to DIC. Indeed, glycocalyx
degradation upsets the interplay between blood and the anticoagulation/anti-thrombotic properties of the glycocalyx.
In particular, removing HS will also remove the bound
antithrombin from the endothelial surface, resulting in increased
fibrin formation, thereby allowing thrombin easier access to
membrane-spanning thrombomodulin to activate protein C. HS
shedding and proteolysis also leads to decreased HS-bound TFPI
in sepsis (49).
Monitoring the progression of glycocalyx damage markers
(e.g., HA or syndecan-1) may prove to be useful to assess the
progression of sepsis and predict survival. Currently, there is
no single biomarker proven to predict sepsis progression or
mortality, and considering the complexity of sepsis, a single
biomarker is not likely to emerge. So far, the enzyme(s)
responsible for HA shedding/degradation from the endothelium
have not been positively identified. More work is required
to positively identify the precise mechanism of HA shedding,
whether it’s enzymatic or chemically induced (e.g., ROS).

Coronavirus Disease 2019
While Coronavirus disease 2019 (COVID-19) is a newly emerged
disease associated with SARS-CoV-2, multiple studies quickly
identified microvascular injury and glycocalyx degradation
as major pathophysiological disease mechanisms. Similar to
bacterial sepsis, COVID-19 glycocalyx damage follows a familiar
pattern and the glycocalyx degradation and endothelial damage
seen in COVID-19 leads to a pro-thrombotic state (33, 50,
51) that in severe cases results in multi-organ thrombosis (50).
Patient thrombosis has a negative effect on patient outcomes (52),
with a thrombotic event being independently associated with
mortality in COVID-19 patients (53, 54). Therapeutic doses of
heparin reduce the likelihood of progression to intubation and
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the glycocalyx (e.g., sulodexide and/or sphingosine-1-phosphate)
may be therapeutically indicated.

molecular weight (pro-inflammatory) and bound with interalpha inhibitor protein, suggesting that free HA in COVID-19
plasma is a degradation product of ECs rather than increased
HA release. HA and hyaluronidase plasma concentrations
showed moderate correlations with SOFA score in COVID-19
patients. Studies utilizing cultured endothelial cells treated with
COVID-19 patient plasma in vitro showed similar changes in
HA, as well as hyaluronidase, MMP2, MMP9, and cathepsin
activity (60).
Several studies suggest that blood markers of glycocalyx
degradation are correlated with disease severity in COVID-19
patients. Serum syndecan-1 concentrations within the first day
of ICU admission were significantly higher in non-surviving
COVID-19 patients compared to survivors (61). The optimal
cut-off value to distinguish survivors was 813.8 ng/mL, as
determined by ROC analysis, and Kaplan-Meier analysis showed
significantly worse outcomes in COVID-19 patients over the
cut-off. Another study found that plasma heparanase activity
and plasma heparan concentration were higher in COVID19 patients compared to healthy controls, and that heparanase
activity was significantly higher in ventilated ICU COVID
patients vs. non-ICU COVID patients (62). Plasma syndecan1 was significantly higher in COVID-19 patients classified
as “critical” compared to those in the “severe” category;
a difference that persisted for 14 days of ICU admission
(63). A further study showed plasma HS concentrations
were increased in COVID-19 patients compared to healthy
controls (59, 64) and were associated with the severity of
disease (64).
Even in convalescent COVID-19 patients who were never
hospitalized, a persistent increase in serum syndecan-1
concentrations compared to healthy controls was found at
a mean of 88 days post symptom onset, and was not significantly
different from currently hospitalized COVID-19 patients (65).
Another study found decreased glycocalyx thickness (using
sublingual perfused boundary region) 4 months after COVID19 infection (none required mechanical ventilation), which
was similar to untreated hypertensive patients (66). While
these studies contained relatively few subjects, they suggest
glycocalyx degradation also occurs in mild cases of COVID-19,
and elevated degradation products can persist for months
after acute illness.
SARS-CoV-2 causes direct endothelial damage via ACE2
receptors, and ACE2 activation may be modulated by the health
and thickness of the glycocalyx (67). In fact, the SARS-CoV-2
spike protein requires HS to aid ACE2 binding (68), a thick,
healthy glycocalyx may act as a physical barrier, extending beyond
the ACE2 receptor and preventing the virus from accessing
the EC (67). However, by the time COVID-19 patients exhibit
viremia, one would expect the disease to be advanced and the
glycocalyx to be severely damaged via the inflammatory response.
Taken together, the published studies strongly suggest that the
glycocalyx clearly undergoes a significant amount of degradation
from COVID-19, likely contributing to platelet adhesion and
increased risk of thrombosis seen in many cases of COVID-19.
Thus, therapies to inhibit platelet adhesion (e.g., administration
of nitric oxide via inhalation or by a donor) and to protect/restore

Frontiers in Medicine | www.frontiersin.org

Trauma—Fluid Resuscitation
Similar to sepsis and COVID-19, trauma can lead to a
hypercoagulative state due to the interplay of inflammation
and vascular injury. Trauma-induced coagulopathy may begin
with a hypercoagulative state that changes to hypcoagulation,
or vice-versa, and can depend on several factors including the
extent of trauma, the amount and rate of intravascular fluid
administered, and the presence of excess fibrinolysis (69, 70).
However, as seen below, trauma is consistently associated with
glycocalyx degradation. Interestingly, in a subset of trauma
patients, glycocalyx degradation, and the release of heparinlike GAGs, including HS, has been suggested to contribute to
hypocoagulation, termed auto-heparinization (71). While trauma
is known to increase the plasma concentrations of glycocalyx
components such as HA, HS, CS, and syndecan-1 compared to
healthy controls (72), it is less well known how the glycocalyx
is affected by fluid resuscitation. Previous strategies to quickly
resuscitate with large amounts of isotonic fluid may not be as
beneficial as conservative strategies (73) and may lead indirectly
to extra glycocalyx shedding.
Plasma syndecan-1 concentration in trauma patients upon
arrival to the emergency department was an independent
predictor of mortality after adjusting for age and injury severity
(74). Patients above the median syndecan-1 concentration
also showed increased markers of inflammation, endothelial
activation/injury and fibrinolysis. Trauma patients with a
lower plasma colloidal pressure, secondary to uncontrolled
hemorrhage together with saline resuscitation, also had increased
plasma HA and syndecan-1 compared to trauma patients with
normal colloidal pressure (72). Blood syndecan-1 concentrations
were elevated in trauma patients after admission to the
emergency department, and those with above average syndecan1 concentrations, had more indicators of microcirculatory
dysfunction (75). While microcirculatory dysfunction improved
over time and syndecan-1 concentrations decreased, syndecan-1
remained elevated for 30–50 h compared to healthy controls (75).
Trauma patients in the highest quartile of plasma syndecan1 concentration upon admission to the emergency department
had the highest rates of blood transfusion and 30-day inhospital mortality (76). In fact, a blood concentration of 40
ng/mL syndecan-1 maximized sensitivity and specificity in
predicting 24-h in-hospital mortality. Further, patients with
plasma syndecan-1 ≥ 40 ng/mL were significantly more injured
and had lower median systolic blood pressures and platelet counts
(76). Higher plasma syndecan-1 levels translated into poorer
outcomes, needing 4 times more blood products, having fewer
hospital ventilator-free days and greater mortality.
Syndecan-1 seems to be the most well-studied glycocalyx
degradation marker in trauma, however, a small study showed
plasma HA concentrations are also significantly associated with
acute traumatic coagulopathy and markers of coagulopathy (77).
While trauma itself degrades the glycocalyx, the choice of
solution for intravenous resuscitation also contributes. When
healthy subjects were administered 0.9% saline, Hartmann’s
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mannitol. Importantly, the glycocalyx thinning was ameliorated
by co-infusion of the antioxidant N-acetyl cysteine, suggesting
an important role for ROS. In another study, baseline systemic
glycocalyx thickness was significantly decreased in type-1
diabetes patients, compared to controls; and there was a further
decrease in type-1 diabetes patients with microalbuminuria
(90). The measure of systemic glycocalyx thickness significantly
correlated (r = 0.73, p < 0.01) with sublingual glycocalyx
thickness measurements (90). Plasma HA concentrations were
also increased in type 1 diabetes patients compared to controls,
and again microalbuminuria increased this further (90). In
contrast, another trial of 136 type-1 diabetes patients failed to
show an association between glycocalyx thickness in sublingual
micro-vessels and the level of albuminuria, although the diabetes
patients did have a significantly decreased glycocalyx compared
to controls (91).
Similar to type-1 diabetes, patients with type-2 diabetes
showed a thinner baseline glycocalyx in sublingual and retinal
vessels compared to normal controls; additionally these patients
had increased plasma HA and hyaluronidase concentrations
(92). First degree relatives of type-2 diabetes patients that
are insulin resistant, and subjects with dysglycemia showed a
lower baseline glycocalyx thickness in sublingual microvessels
compared to normal controls (93). Furthermore, the glycocalyx
acutely thinned in these subjects during oral glucose tolerance
tests, while the thinning was not observed in healthy subjects (93).
While most glycocalyx studies in diabetes have focused on HA,
plasma syndecan-1 levels are also significantly increased in type2 diabetes patients compared to controls (94). Of the diabetes
patients, mean fasting blood glucose was 10.32 mM and 29.3%
had glucose in their urine. Another study of type-1 diabetes
patients found significantly increased plasma concentrations
of syndecan-1 in those with nephropathy compared to type-1
patients without (95). Again, the nephropathy patients’ mean
glycated hemoglobin was 9.18% vs. 7.58% for controls (normal
4–5.6%), suggesting the nephropathy patients blood glucose was
not well controlled. Contrary to this, blood syndecan-1 levels in
type-1 diabetic patients with microalbuminuria were increased
as compared to patients without, and healthy controls, but no
difference in glycated hemoglobin was found (96).

solution, 4% and 20% albumin in a double-blind crossover study,
only the 0.9% saline produced evidence of glycocalyx degradation
through increased plasma syndecan-1 (78). Though the fluid
treatment was relatively mild in healthy subjects, it suggested
that 0.9% saline, the most widely used resuscitation fluid globally,
may be the harshest on the endothelial glycocalyx integrity.
Indeed, normal saline was associated with poorer outcomes
as compared to other crystalloids in critically ill adults (79),
though glycocalyx integrity was not specifically investigated.
Additionally, an in vitro study suggests hypernatremia, can be
associated with normal saline infusion, damaging the endothelial
glycocalyx, releasing HA and syndecan-1 (80).
Hemorrhagic shock patients showed significantly increased
plasma syndecan-1 concentrations after their injury compared
to healthy controls (81). After resuscitation with fresh frozen
plasma, syndecan-1 significantly decreased, but it was still
elevated over healthy controls (81). This latter response could
be due, at least in part, to dilution by the administered fresh
frozen plasma; however, in vitro studies suggest that fresh frozen
plasma reduces endothelial permeability and aids syndecan-1
restoration (81). Indeed, administration of fresh frozen plasma to
non-bleeding critically ill patients (45% sepsis patients) resulted
in a significantly lower syndecan-1 plasma concentration when
compared to plasma levels obtained before transfusion (565 vs.
675 pg/mL) (82). As cytokine/chemokine plasma concentrations
were unaffected, and ADAMTS13 concentrations were increased,
this latter data suggested that the reduced plasma syndecan-1
concentration was not dilutional. When patients with thoracic
aortic dissection received an intravenous product made from
pooled, solvent and detergent-treated plasma (OctaplasLG)
during surgical repair, their plasma syndecan-1 levels were
significantly reduced, indicating less glycocalyx injury (83).
The resuscitation of hemorrhagic trauma patients favors a
saline-restricted approach, and emphasizes balanced transfusions
that include fresh frozen plasma. While many studies have
measured syndecan-1 concentrations after fluid resuscitation,
most measured only a single time point after resuscitation
and few monitored a time-course. Thus, the positive effects
of fresh frozen plasma on the vascular glycocalyx requires
further investigation.

Diabetes

STRATEGIES/THERAPIES FOR
PROTECTING/RESTORING
GLYCOCALYX

Glycocalyx degradation in diabetes (e.g., hyperglycemia)
or diabetes-associated complications [e.g., the systemic
inflammatory response associated with diabetic ketoacidosis
(84–87)] has not been studied as extensively as compared to other
diseases with a severe inflammatory component. Nevertheless,
the current knowledge indicates that the endothelial glycocalyx
is degraded by acute hyperglycemia and that the endothelial
glycocalyx thinning due to hyperglycemia contributes to
impaired wound healing in diabetes patients (88).
In a small study of healthy males, acute hyperglycemia
induced by a concentrated glucose infusion decreased systemic
endothelial glycocalyx thickness, an observation that coincided
with a rapid increase in circulating plasma levels of HA (89).
This glycocalyx thinning was independent of rapid changes in
osmolality, as the glycocalyx did not degrade in response to
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Because of the extended time-course of glycocalyx recovery (97),
and in light of the apparently long-lasting glycocalyx effects
of COVID-19 (65, 66), therapies that protect the endothelial
glycocalyx or support its replacement would be advantageous.
Currently, there is limited data on trials or therapies in humans,
likely due to the relatively brief time since the endothelial
glycocalyx has gained prominence and the long timelines for
clinical research. Many excellent basic science and pre-clinical
models have emerged and have recently been reviewed elsewhere
(98, 99) so here we will focus primarily on therapies which
have human data.
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Steroids

an important target to rescue the glycocalyx. Despite
musculoskeletal syndrome as a side effect of early broadspectrum MMP inhibitors, several more selective MMP
inhibitors, particularly those that inhibit MMP-2 or –9, have
shown clinical benefit (108). These latter MMP inhibitors are
protein-based, including antibodies and tissue inhibitors of
MMPs (TIMPs), several of which are currently undergoing
clinical trials (109), including an anti-MMP-9 antibody (110).
Small peptide inhibitors of ADAM-17, which cleaves syndecan-1
and 4, have also been identified as potential therapeutics (109).
Due to the hypercoagulation that often accompanies critical
illnesses, and because thrombin cleaves syndecan-4 (37) it is a
rational a target for treatment. While direct thrombin inhibitors
have not been specifically evaluated in trials of glycocalyx
degradation, there are several compounds available for human
use which may provide therapeutic benefit (111, 112).
Finally, the protease inhibitor Ulinastatin, which inhibits
lipopolysaccharide-induced heparanase expression and activity,
suppressed vascular permeability and HS degradation in mouse
models (98).

Glucocorticoids have a long history as anti-inflammatory
agents; decreasing pro-inflammatory molecule release and
reducing extravasation of white blood cells, making steroids an
attractive agent for indirectly protecting the glycocalyx. A small
trial showed pre-surgical administration of hydrocortisone to
patients undergoing cardiac surgery with cardiopulmonary
bypass significantly decreased plasma concentrations of heparan
sulfate, but not syndecan-1, when compared post-operatively to
untreated controls (100). Recently, a phase 2 study investigated
the preoperative administration of dexamethasone on abdominal
surgery patients with or without albumin, and found that
there was no difference in post-operative day 1 plasma
syndecan-1. However, the dexamethasone plus albumin group
did have lower plasma heparan sulfate (101) concentrations.
While this was a small trial with a total of 72 patients, and
the improved glycocalyx markers were not substantial, the
experimental treatment was well tolerated and there were fewer
complications in the experimental group suggesting that the
results may improve with different formulations. A single preoperative dose of methylprednisolone was shown to cause a
modest, but significant reduction in post-operative syndecan1 concentrations compared to controls in patients undergoing
total knee arthroplasty (102). As the studies examining the
effects of steroids on the glycocalyx have focused on surgical
outcomes, it is unclear if they would be effective in critical illness
and prolonged inflammation. Critically ill COVID-19 patients
respond well to steroid therapy, and glycocalyx degradation is
a key pathophysiological mechanism in these patients, raising
the possibility that the glycocalyx may be a potential steroid
target (103).

Heparinoids/Glycosaminoglycans
Prophylactic administration of low molecular weight heparin
lowered heparanase activity in non-ICU COVID-19 patients,
though no differences in plasma HS were found, and it did not
affect heparanase activity in ventilated COVID-19 patients (62).
Other glycocalyx markers were not measured. Heparin can act
to protect the glycocalyx in vitro and even help reconstitute it by
mobilizing syndecan-1 (113).
Endogenous plasma hyaluronidase inhibitors increased
during sepsis (18), suggesting exogenous inhibitor addition may
be of benefit. The heparinoid Sulodexide is a heterogeneous
mixture of sulfated glycosaminoglycans and acts as a heparinase
inhibitor. Two months of Sulodexide treatment, increased
sublingual, and retinal glycocalyx thickness in type-2 diabetes
patients without increased plasma HA concentrations (92).
A recent meta-analysis concluded that Sulodexide was renoprotective and decreased albumin excretion rate by 50% in
patients with diabetic nephropathy (114). Since glycocalyx
degradation in kidney endothelial cells was suspected to play
a role in the pathogenesis of diabetic nephropathy (115), this
latter finding suggested that Sulodexide may have restored the
glycocalyx. Additionally, this data suggested that hepariniod
therapy may be useful in the context of the long-term damage
associated with COVID-19 (66, 67). Currently, heparin is often
used as an anticoagulant in sepsis and COVID-19 patients;
however, we are unaware of studies that have measured its effect
on the glycocalyx in these diseases.

Protease Inhibitors
A variety of proteases cleave syndecans and CD44 (see
Table 1), making proteases an attractive target for reducing
glycocalyx degradation and/or aiding the glycocalyx recovery.
Tranexamic acid is a synthetic lysine derivative that inhibits
plasminogen activation and its binding to fibrin, thereby
inhibiting fibrinolysis (104). A recent study showed pre- and
peri-operative administration of tranexamic acid in patients
undergoing posterior lumbar fusion surgery significantly
inhibited the 2 h postoperative increase in plasma syndecan-1
compared to untreated patients (105). A study of patients with
moderate to severe traumatic brain injury showed a modest
but significant decrease in plasma syndean-1 when tranexamic
acid was administered within 2 h postinjury (106). While the
exact mechanism of syndecan-1 preservation is unknown, it has
been suggested from in vivo experiments that tranexamic acid
additionally inhibits MMP activity (107) as well as fibrinolysis.
Tranexamic acid’s effect on the glycocalyx in critical illness has
not been thoroughly studied, and although its effect limiting
syndecan-1 shedding is promising, its action of inhibiting
fibrinolysis (104) suggests it may be incompatible with conditions
exhibiting DIC where it may stabilize pathological clots.
The relatively large number of MMPs which can cleave
syndecans-1 and 4, and CD44 (Table 1) make MMPs
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Resuscitation Strategies
Volume resuscitation with plasma or plasma products has
recently gained attention. As discussed above (Trauma—
Fluid resuscitation), administering fresh frozen plasma to nonhemorrhagic critically ill patients protected the glycocalyx (82);
although plasma treatment for sepsis has been generally not
recommended (116). Fluid resuscitation of septic shock patients
with albumin-supplemented crystalloids did not affect plasma
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Activation of the Tie2 receptor in vitro may promote recovery of
the endothelial glycocalyx (125); in fact, the Tie2 agonist AV-001
is currently in a phase 2a trial for patients with severe COVID-19
(clinicaltrials.gov ID NCT05123755).

syndecan-1 concentrations, although there was some possible
endothelial protections (46). Moreover, a rodent hemorrhage
model suggested albumin administration may partially restore
the glycocalyx (117) and a pilot study in human septic
shock patients indicated that an albumin infusion may restore
endothelial function (118).
Sphingosine 1-phosphate has been shown to correlate with
positive outcomes in septic shock (46), and the glycocalyx
protective effects of plasma or its products may be a result of the
sphingosine 1-phospate present in those products (99).
Although two recent clinical trials demonstrated early prehospital plasma administration to trauma patients conferred
a significant survival benefit (119), there was no analysis
of endothelial glycocalyx markers. Fresh frozen plasma was
shown to help restore endothelial syndecan-1 in vitro (81), and
another study showed early plasma resuscitation can restore
the glycocalyx, as opposed to late plasma treatment that was
ineffective (120). As discussed above, glycocalyx degradation was
reduced by administration of OctaplasLG, as compared to fresh
frozen plasma in patients undergoing emergency surgery for
thoracic aorta dissection (83). Rodent studies of hemorrhagic
shock indicated that plasma resuscitation (either fresh or freshfrozen) protected or restored the endothelial glycocalyx, where
lactated Ringer’s or hydroxyethyl starch solution did not, and
increased survival may have been dependent on syndecan-1
restoration [Reviewed in (121)].

CONCLUDING REMARKS
Several major glycocalyx components have been used as
biomarkers to distinguish sub-populations in critical illness or
predict outcomes. Glycocalyx degradation occurs during critical
illness/injury, but it is not the only pro-inflammatory and prothrombotic change to take place, and it must be viewed in context
with other microvascular pathologies, endothelial dysfunction,
leukocyte/platelet adhesion, and the release of inflammatory
mediators, such as cytokines, proteases and ROS. Furthermore,
glycocalyx degradation may not be a general response to
inflammation; in fact, in some pathologies it may offer disease
specific consequences (i.e., trauma-induced auto-heparinization
vs. sepsis-induced DIC). Despite an abundance of basic and
pre-clinical research into glycocalyx preserving and rebuilding
strategies, there remains a lack of clinical trials in humans.
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Anti-inflammatory Therapies
Prophylactic administration of a TNF-α inhibitor ameliorated
glycocalyx degradation in response to low-dose endotoxin
in healthy volunteers (12), and a combination therapy of
methotrexate and/or a TNF-α inhibitor in rheumatoid arthritis
patients decreased syndecan-1 for greater than 6 weeks (122).
However, whether TNF-α inhibition would be beneficial to the
glycocalyx in the often more severe inflammation observed in
critically ill patients is undetermined, although the history of
TNF-α inhibition trials (123, 124) in sepsis would suggest not.
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